S01BC05 ketorolac
SENSORY ORGANS ›OPHTHALMOLOGICALS ›ANTIINFLAMMATORY AGENTS ›Antiinflammatory agents, non-steroids
健保收載品項 FDA 已核准 TFDA 在效許可證 4 健保給付條款 1
健保收載品名:"派頓" 克多樂眼藥水 0.5%、"聯邦"樂寧痛眼藥水 0.5%w/v、克炎多樂點眼液 0.5%、可特樂點眼液、愛克樂眼藥水0.5% W/V、舒腫眼藥水 0.5%
FDA 適應症
1 INDICATIONS AND USAGE Omidria ® is added to an ocular irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain. OMIDRIA is an alpha 1-adrenergic receptor agonist and nonselective cyclooxygenase inhibitor indicated for: Maintaining pupil size by preventing intraoperative miosis ( 1 ) Reducing postoperative pain ( 1 ) OMIDRIA is added to an ocular irrigating solution used during cataract surgery or intraocular lens replacement.
資料來源:openFDA(美國 FDA Structured Product Labeling)。為英文原文,僅供對照。
TFDA 適應症
NHI 給付規定
直接適用條款
§ 14.8 Ketorolac tromethamine(如Acular Ophthalmic Solution):(89/11/1)
眼科製劑 › Ketorolac tromethamine(如Acular
Ketorolac tromethamine(如Acular Ophthalmic Solution):(89/11/1) 限白內障手術後之眼部發炎使用。
歷史演變(1 次異動)
| 生效日 | 異動說明 |
|---|---|
| 89/11/1 | legacy_boan_parsed:ch14.txt |
實證補充
本藥品尚無實證補充整理(未來新增 Review/指引知識時補列)。
FDA 段:openFDA US SPL · TFDA 段:食藥署西藥許可證+ATC 分類開放資料 · NHI 段:健保署「全民健康保險藥品給付規定」(更新日 2026-05-31)· 實證補充段:人工彙整。 本頁為資訊整理,實際給付與適應症以主管機關公告為準。